AAVantgarde生物

2023年6月8日

一轮新的€6100万AAvantgarde生物,研究活动的副产品Tigem Telethon遗传学和医学研究所(),位于那不勒斯和Sofinnova合作伙伴的支持下,承销了种子轮通过Sofinnova电视节目的基金在2021年7月。新一轮为首的联合风险投资基金阿特拉斯风险和Forbion,从洛伍德参与基金和投资者Sofinnova成立合作伙伴。第一轮已经在2021年10月以来管道。阅读更多关于AAvantgarde生物并找到一天中最重要的金融新闻与Born2Invest移动应用,并发,Jason Rhodes的阿特拉斯,德米特里Hristodorov Forbion,和洛伍德的大卫·斯坦伯格基金将加入AAvantgarde生物的董事会AAvantgarde生物,总部设在米兰,意大利,产生基因疗法对遗传性视网膜疾病。创始人,阿尔贝托Auricchio教授,是一个高度认可科学家和基因治疗领域的先驱。公司的技术是基于现有平台基于腺相关病毒(装甲防护),是主要的病毒载体技术用于基因治疗的应用。AAVantgarde AAV-based大型基因传递有两个专有平台:利用DNA重组,称为双混合,和蛋白质trans-splicing之一,称为AAV intein。公司验证平台两个主要程序:开创syndrome-associated色素性视网膜炎类型1 B (Usher1B),使用双混合,和黄斑变性疾病,使用一个AAV intein。资金将支持完成概念验证(POC)第一次作用于人体研究AAV intein Usher1B主题和进一步发展的计划和进入诊所黄斑变性疾病。该公司还计划去追求眼科外的项目。 “This funding represents a pivotal moment in our mission to help patients, and we are excited to work with our new and founding investors to advance our platforms and pipeline,” said Natalia Misciattelli, chief executive officer of AAVantgarde, who added: “The completion of this round with such a distinguished group of life science investors is an acknowledgment of the importance of AAVantgarde’s unique technology, which will initially be used to help patients suffering from the debilitating impact of blindness associated with Usher1B syndrome and Stargardt disease.” “AAV gene therapy has been limited by transgene capacity, whereas AAVantgarde’s proprietary platforms enable the delivery of large genes to tissues and cells in vivo, which could extend to many disease areas,” said Jason Rhodes, partner at Atlas Venture. “AAVantgarde has a clear mission to bring next-generation genetic drugs to underserved patients with debilitating diseases, bringing hope to patients with inherited retinal diseases with Usher1B syndrome and Stargardt disease to improve vision,” concluded Dmitry Hristodorov of Forbion. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures . First published in Be Beez , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.